resveratrol has been researched along with arginyl-glycyl-aspartic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Koutsas, C; Liakopoulou-Kyriakides, M; Sarigiannis, Y; Stavropoulos, G | 1 |
| Hsieh, TC; John Bennett, D; Wong, C; Wu, JM | 1 |
| Guo, L; Long, Q; Pu, L; Zhu, W | 1 |
3 other study(ies) available for resveratrol and arginyl-glycyl-aspartic acid
| Article | Year |
|---|---|
Conjugation of resveratrol with RGD and KGD derivatives.
Topics: Catalysis; Chromatography, High Pressure Liquid; Dicyclohexylcarbodiimide; Esterification; Humans; Lysine; Oligopeptides; Resveratrol; Spectrometry, Mass, Electrospray Ionization; Stilbenes | 2007 |
Regulation of p53 and cell proliferation by resveratrol and its derivatives in breast cancer cells: an in silico and biochemical approach targeting integrin αvβ3.
Topics: Anticarcinogenic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Estrogen Receptor alpha; Female; Flow Cytometry; Humans; Integrin alphaVbeta3; Mitogen-Activated Protein Kinases; Oligopeptides; Resveratrol; Signal Transduction; Stilbenes; Tumor Suppressor Protein p53 | 2011 |
RGD-Conjugated Resveratrol HSA Nanoparticles as a Novel Delivery System in Ovarian Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Oligopeptides; Ovarian Neoplasms; Resveratrol; Serum Albumin, Human | 2020 |